ADVERTISEMENT
ADVERTISEMENT

Attacking b-Amyloid at its Source

The all-out assault to impede production of b-amyloid (Ab), the plaque-forming peptide believed by many to cause neurodegenerative Alzheimer's disease (AD), entails a war on two fronts. For those aiming to prevent plaques at their cellular source, the two clear targets are b-secretase and g-secretase, which sequentially cleave amyloid precursor protein (APP) to generate Ab. Some victories are emerging: Small molecules designed to inhibit g-secretase activity are being clinically tested, and the

Brendan Maher
The all-out assault to impede production of b-amyloid (Ab), the plaque-forming peptide believed by many to cause neurodegenerative Alzheimer's disease (AD), entails a war on two fronts. For those aiming to prevent plaques at their cellular source, the two clear targets are b-secretase and g-secretase, which sequentially cleave amyloid precursor protein (APP) to generate Ab. Some victories are emerging: Small molecules designed to inhibit g-secretase activity are being clinically tested, and the 1999 identification and cloning of b-secretase led researchers to design small molecule inhibitors.

Courtesy of John Q. Trojanowski

Guilty by Association: While researchers are not yet certain of the causative agent in Alzheimer's, insoluble peptides like Ab aggregate outside the neural cells to form amyloid plaques associated with the disease.



g-secretase, which has made it farthest as a drug target, still has an identity problem. One camp...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT